Article Information
History
- January 26, 2018.
Article Versions
- Version 1 (January 26, 2018 - 09:30).
- You are viewing Version 2, the most recent version of this article.
Copyright
The copyright holder for this preprint is the author/funder, who has granted bioRxiv a license to display the preprint in perpetuity. This article is a US Government work. It is not subject to copyright under 17 USC 105 and is also made available for use under a CC0 license.
Author Information
- Pedro Torres-Ayuso1,7,
- Sudhakar Sahoo2,
- Melanie Galvin3,
- Hui Sun Leong2,
- Kristopher K Frese3,
- Andrew Hughes4,
- Richard Marais5,6,
- Caroline Dive3,6,
- Matthew G Krebs4,6 and
- John Brognard1,7,*
- 1Signalling Networks in Cancer Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
- 2Computational Biology Support Team, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK
- 3Clinical and Experimental Pharmacology Group; Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK;
- 4Division of Molecular and Clinical Cancer Sciences, Faculty of Biology, Medicine and Health, The University of Manchester and Experimental Cancer Medicine Team, The Christie NHS Foundation Trust, Manchester, M20 4BX, UK;
- 5Molecular Oncology Group, Cancer Research UK Manchester Institute, The University of Manchester, Manchester M20 4BX, UK;
- 6Cancer Research UK Manchester Experimental Cancer Medicines Centre, The University of Manchester, Manchester M20 4BX, UK;
- 7Signaling Networks in Cancer Section, Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702
- ↵*Correspondence to: Dr. John Brognard, Signaling Networks in Cancer Section, Laboratory of Cell and Developmental Signaling, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702, USA. Tel: +1-301-846-1163 E-mail: john.brognard{at}nih.gov
Posted January 26, 2018.
Signaling pathway screening platforms are an efficient approach to identify therapeutic targets in precision-medicine oriented early phase clinical trials
